The global Virus Filtration market size is expected to reach close to $ 8.35 Billion by 2029 with an annualized growth rate of 12.6% through the projected period.
One of the main factors leading to development is the growing incidence of chronic diseases. The need for biologics is expected to be driven by an increased incidence of chronic diseases, including cancer, diabetes, and autoimmune disorders. Around 14.1 million new cases of cancer were diagnosed worldwide in 2012, according to the International Organization for Research on Cancer, and this figure is expected to reach 21.7 million by 2030. Thus, there is an increasing market for therapeutic biologics, which subsequently fuels the demand for R&D and manufacturing applications for virus filtration devices.
Another key factor expected to fuel the demand is compliance with drug development and production regulatory mechanisms such as current good manufacturing practise (cGMP) regulations. Virus protection of these products is maintained by producers by multiple quality management initiatives such as raw materials inspection and quality control, certification and enforcement of successful virus clearance t Thus, for production and R&D activities, the market for these goods is very strong. CROs partner with biotechnology and biopharmaceutical firms to produce experimental medicines and treatments, which are also projected to help the expansion of the market.
Virus Filtration Market Scope
Metrics | Details |
Base Year | 2023 |
Historic Data | 2018-2020 |
Forecast Period | 2024-2029 |
Study Period | 2018-2029 |
Forecast Unit | Value (USD) |
Revenue forecast in 2029 | USD 8.35 Billion |
Growth Rate | CAGR of 12.6% during 2021-2029 |
Segment Covered | By Product, Technology, Application, Region |
Regions Covered | North America, Europe, Asia Pacific, South America, Middle East and Africa |
Key Players Profiled | Merck KGaA, GE Healthcare, Thermo Fisher Scientific Inc., Lonza Group Ltd., Pall Corporation, Charles River Laboratories International, Inc., Sigma-Aldrich Corporation, Sartorius AG, Asahi Kasei Medical Co., Ltd., and WuXi PharmaTech (Cayman) Inc. |
Key segments of the global virus filtration market
Product Overview, (USD Billion)
- Consumables
- Instruments
- Services
Technology Overview, (USD Million)
- Filtration
- Chromatography
Application Overview, (USD Million)
- Biologicals
- Medical devices
- Water purification
- Air purification
Regional Overview, (USD Million)
- North America
- U.S.
- Canada
- Europe
- Germany
- United Kingdom
- France
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
Reasons for the study
- Increasing Government Support for the Pharmaceutical & Biotechnology Industry
- Growth in Biopharmaceutical Industry
What does the report include?
- The study on the global virus filtration market includes analysis of qualitative market indicators such as drivers, restraints, challenges and opportunities
- Additionally, the market competition has been evaluated using the Porter’s five forces analysis
- The study covers qualitative and quantitative analysis of the market segmented on the basis of Product, Technology, Application. Moreover, the study provides similar information for the key geographies.
- Actual market sizes and forecasts have been provided for all the considered segments
- The study includes the profiles of key players in the market with a significant global and/or regional presence
Who should buy this report?
- The report on the global virus filtration market is suitable for all the players across the value chain including raw material suppliers, virus filtration providers, pharmaceutical and medical device manufacturers, distributors, suppliers and retailers
- Venture capitalists and investors looking for more information on the future outlook of the global virus filtration market
Consultants, analysts, researchers, and academicians looking for insights shaping the global virus filtration market
Frequently Asked Questions (FAQ) :
The protection of viruses in biotech and plasma-derived therapeutics is assured by complementary development and quality management steps, including control and inspection of raw materials, validation and application of appropriate virus clearance technologies, and monitoring of the existence of viruses in the finished product. A typical unit process in the manufacture of biological products is virus filtration, which is considered a durable and efficient virus clearance technology.
In order to preserve viral particles, virus filtration employs a membrane barrier. It is a form of removal depending on size that uses a specially engineered polymeric membrane to preserve particles of viruses on the surface and inside the membrane pores. Usually, the log reduction value (LRV) and the throughput are the critical efficiency parameters.
The global market is segmented on the basis of product, technology, application. The product segment is further broken down to consumables, instruments, and services. The technology segment is further broken down into filtration and chromatography. The application segment is broken down into biologicals, medical devices, water purification, air purification.
In 2019, consumables dominated the global market on account f its highest consumption for viral filtration techniques. Regular use across all the applications is the major factor for segment growth.
It is expected that the services segment will display the highest CAGR during the study period. This is attributed to expanded biotechnology firms' outsourcing of R&D and drug production facilities from CROs. In addition, CROs partner with biotechnology and biopharmaceutical firms to create innovative medicines and treatments that are projected to sustain development in the segment.
On the basis of region, the global market is classified into North America, Europe, Asia Pacific, Central & South America, and Middle East and Africa. As of 2018, North America accounted for the dominant share compared to other regional markets, and is projected to retain its domination throughout the forecast period. The presence of large scale suppliers, well-established healthcare facilities, and high recognition among the surgeons culminated in this region's growing acceptance of the process. Because of the strong demand for novel virus filtration products for research and the growth and manufacture of biologics, Europe was the second largest market. Furthermore, the international sector is projected to be powered by highly developed healthcare infrastructure and large-scale developments in R&D, mainly in Germany, the UK and France.
Key players in the market include Merck KGaA, Danaher, Thermo Fisher Scientific Inc, GE Healthcare, Charles River Laboratories International, Inc, WuXi PharmaTech, and many more. To gain revenue share in the industry, leading producers are engaged in mergers and acquisitions, strategic partnerships, and novel product growth. Mergers and acquisitions assist companies in growing their current market and global presence. For example, Danaher Corporation completed the acquisition of Pall Corporation, a leading supplier of products for virus filtration, in August 2015.